Immatics N.V.: Considering More Engineered T Cells For Cancer
Source: SeekingAlpha
2025-01-12 03:28:22 ET
Summary
- Immatics N.V., a German biotech, focuses on training T-cells to target cancer, with a promising pipeline led by IMA203 targeting PRAME in solid tumors.
- IMA203 shows a 54% response rate in metastatic melanoma; phase 3 SUPRAME trial aims for 2026 interim analysis, targeting progression-free survival.
- Financially strong with assets to fund operations until at least 2027, reducing the need for unfavorable market fundraises.
- Despite promising data, market impatience and relatively long timelines suggest waiting for a better entry point before investing.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Immatics N.V.: Considering More Engineered T Cells For Cancer
Immatics N.V.
NASDAQ: IMTX
IMTX Trading
-0.61% G/L:
$11.37 Last:
87,110 Volume:
$11.48 Open:
IMTX Latest News
May 30, 2026 08:00:00 am
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
May 12, 2026 07:00:00 am
Immatics Announces First Quarter 2026 Financial Results and Business Update
IMTX Stock Data
$1,341,978,928
63,814,383
N/A
32
N/A
Biotechnology & Life Sciences
Healthcare
DE
Tbingen
